Immune Regulation

OverviewSuggest Edit

Immune Regulation is a clinical-stage biotech company providing technologies for resetting the immune system and developing therapies for inflammatory and immunological diseases. Its drug immune-resetting therapies reset the immune system from a pro-inflammatory to a regulatory state to induce long-term disease remission in patients with allergic and immune-mediated diseases.
TypePrivate
Founded2011
HQGreat Shelford, GB
Websiterevolobio.com

Latest Updates

Employees (est.) (Nov 2021)26
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Immune Regulation

Roly Foulkes

Roly Foulkes

Chief Scientific Officer
Jonathan Rigby

Jonathan Rigby

Group Chief Executive Officer and Director
Perry Calias

Perry Calias

Chief Operating Officer
Jonathan Gold

Jonathan Gold

Chief Financial Officer
Jones W Bryan

Jones W Bryan

Chief Business Officer
Jeff Myers

Jeff Myers

Chief Medical Officer
Show more

Immune Regulation Office Locations

Immune Regulation has an office in Great Shelford
Great Shelford, GB (HQ)
Windsor House, Station Court, Station Rd
Show all (1)

Immune Regulation Financials and Metrics

Summary Metrics

Founding Date

2011

Immune Regulation total Funding

$52.4 m

Immune Regulation latest funding size

$52.44 m

Time since last funding

a year ago

Immune Regulation investors

Immune Regulation's latest funding round in September 2020 was reported to be $52.4 m. In total, Immune Regulation has raised $52.4 m
Show all financial metrics

Immune Regulation Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

SecurityScorecard logo

Immune Regulation Online and Social Media Presence

Embed Graph

Immune Regulation News and Updates

Immune Regulation to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

LONDON AND NEW ORLEANS, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Immune Regulation, LTD, announced today that the company will give a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:30 a.m. EST.

Morningside Ventures leads Series B funding in biotech firm Immune Regulation

The round also saw the participation of existing shareholders including 24Haymarket. The post Morningside Ventures leads Series B funding in biotech firm Immune Regulation appeared first on DealStreetAsia.

Immune Regulation Frequently Asked Questions

  • When was Immune Regulation founded?

    Immune Regulation was founded in 2011.

  • Who are Immune Regulation key executives?

    Immune Regulation's key executives are Roly Foulkes, Jonathan Rigby and Perry Calias.

  • How many employees does Immune Regulation have?

    Immune Regulation has 26 employees.

  • Who are Immune Regulation competitors?

    Competitors of Immune Regulation include X-Chem, Corestem and Kangstem Biotech.

  • Where is Immune Regulation headquarters?

    Immune Regulation headquarters is located at Windsor House, Station Court, Station Rd, Great Shelford.

  • Where are Immune Regulation offices?

    Immune Regulation has an office in Great Shelford.

  • How many offices does Immune Regulation have?

    Immune Regulation has 1 office.